Qvanteq Company
Qvanteq is a Swiss medtech startup that develops bioactive stents to address the side effects of currently available coronary and endovascular stents. Its Qstent controls in-growth to reduce the risk of restenosis and thrombosis. The company was founded in 2009 and is privately held, with ISO 13485 certification. It is a spin-off from the Swiss Federal Institute of Technology and was awarded the CTI start-up label in 2012.
Headquarters:
Zurich
Estimated Revenue:
Less than $1M
Industry:
Medical Technology